1 January 2024
Nirsevimab, a monoclonal antibody, has demonstrated remarkable efficacy in reducing RSV-related hospital admissions in babies by over 80%, according to a large clinical trial. This single-shot treatment offers immediate protection against RSV, a common seasonal virus affecting 90% of childre...